Introduction
Total hip replacement (THR) is classified as at high thrombosis risk (deep venous thrombosis [DVT] and pulmonary embolism [PE] ). American [1] and French [2, 3] consensus conferences recommended prolonged 35-42 days thromboprophylaxis following THR. In France, this has been implemented by injection of low molecular weight heparin (LMWH), with twice-weekly platelet monitoring due to the risk of heparin-induced thrombopenia (HIT). The only oral anticoagulant available was anti-vitamin K (AVK); compliance could be checked on the International Normalized Ratio (INR). However, difficulty of use, narrow implementation window [4] and risk of hemorrhage [5] , mainly due to misuse, led to AVK being abandoned in most cases as a preventive treatment for postoperative thrombosis in orthopedic surgery.
Recently, new oral anticoagulants have come onto the market: dabigatran etexilate (Pradaxa ® ), an anti-IIa, and rivaroxaban (Xarelto ® ), an anti-Xa, with official approval for prescription following THR and total knee replacement (TKR). Apixaban (Eliquis ® ), an anti-Xa, is to come onto the market soon. They are administered orally and do not require blood tests. In addition to comfort for the patient, who no longer undergoes daily injection and weekly blood sampling, cost-saving is also significant [6] .
These oral anticoagulants raise the issue of compliance [7] for the medical community, as their administration is entirely the responsibility of the patient after discharge home. The present study therefore sought to assess compliance to oral thromboprophylaxis following THR and the possible consequences of non-compliance. The hypothesis was that compliance is good throughout the treatment prescribed for non-dependent patients discharged home.
Patients and method

Patients
A prospective continuous cohort study, with university funding and ethics committee approval, included patients undergoing first-line THR in the Caen University Hospital Center (France) between November 2, 2009 and July 28, 2010 and receiving oral dabigatran etexilate, at a single dose of two 110 mg capsules per day. Other inclusion criteria were: age 18-75 years, and consent following written and oral information (although no specific booklet or treatment education was provided). Exclusion criteria were: discharge to another institution, previous long-course anticoagulant treatment, low dabigatran etexilate dose indicated according to the marketing authorization (moderate or severe renal insufficiency (creatinine clearance less than 50 mL/min), liver enzyme (alanine aminotransferase) level more than 2-fold normal threshold, weight less than 50 kg, patient under amiodarone or quinidine), or adult patient under guardianship.
Methods
Thromboprophylaxis was initiated toward the end of the day of the THR. The study as such began at discharge, for 30 ± 5 days (herein, S1 (first day of study, at discharge) to S30 ± 5). At home, each patient had 60 capsules of dabigatran etexilate 110 mg: i.e., 30 days' treatment. An electronic device was glued to each blister of the pack ( Fig. 1 ) and recorded the date and time each capsule was taken (ABR Pharma TM ). Packaging was not otherwise modified.
Assessment
Cognitive status on the Mini-Mental State (MMS) [8] , history and socio-economic activity were recorded at inclusion. A clinical and echo-Doppler check-up for thromboembolic events was performed at S30 ± 5 to analyze the consequences of any non-compliance; any proximal and distal thromboses were noted. At this check-up, the electronic device was analyzed on a dedicated computerized reader. Failure to take one or more capsules or a delay of more than 12 and less than 24 hours was counted as non-compliance. Taking more than two capsules (''over-compliance'') was also counted as non-compliance, although the specific risks entailed are different. Compliance was calculated per day as the ratio between cases of non-compliance in terms of dose or time and the theoretic number of doses.
Statistics
Patients were assigned to one or two categories according to results: compliant or imperfectly compliant. Qualitative variables were compared by Fisher's exact test, and quantitative variables were compared between groups by Anova. The significance threshold was set at 0.05.
Results
One hundred and sixty-eight THRs were performed during the 9 months of the study period; 62 patients were included. Table 1 shows the reasons for exclusion of the other 106. Two of the 62 patients were excluded while in hospital, before the start of the study (one venous thrombosis with curative treatment before discharge; one postoperative THR dislocation with surgical revision). Four of the 60 patients who handed in their electronic device were excluded: two for device defects, one for defective device use, and one who had ceased treatment due to headache (LMWH therapy pursued by the patient's family doctor). Electronic device analysis thus concerned 56 patients ( Fig. 2 ) for a theoretic 3246 capsules between S1 and the day of the clinical/echoDoppler check-up (S30 ± 5). Over the treatment period, 3188 capsules were taken in good compliance with the prescribed time of administration. Overall compliance was 98.21%. Nineteen patients showed one or more cases of non-compliance, including 1 withy ''over-compliance'' (three instead of two capsules on study days 1 and 2) without resultant hemorrhage (Tables 2 and 3 ). Compliance fell regularly over successive 5-day periods ( Fig. 3) but not below 97% between S26 and S30. During the first 10 days (S1-S10), seven patients showed incomplete compliance; six forgot a dose and one ''overcomplied''. Overall compliance for this period was 98.5% (or 98.9% taking account only of the risk of insufficient prophylaxis) (Fig. 4) . Table 4 presents patient data at inclusion and per group (compliant vs. incompletely compliant). Statistical analysis found compliant patients to be significantly more often retired or in early retirement (P = 0.009); retired patients were significantly older (mean, 65.51 ± 4.92 years) than the others (mean, 51.18 ± 8.64 years; P < 00.0001). Patients Table 2 Day of non-compliance after day of discharge (S).
Patient
Reason for non-compliance Day S n capsules concerned 1  Forgot  S20  2  Forgot  S26  2  Forgot  S30  2  5  Forgot  S8  2  14 Over-compliance (3) S1 1 Over-compliance (3)  S2  1  20  Forgot  S18  2  21  Forgot  S13  2  22  Forgot  S8  2  24  Forgot  S12  2  Forgot  S19  2  28  Forgot  S27  2  30  Forgot  S9  2  31  Forgot  S28  2  34  Forgot  S10  2  35  Forgot  S13  2  Forgot  S17  2  Forgot  S18  2  39  Forgot  S14  2  Forgot  S27  2  47  Forgot  S3  2  51  Forgot  S30  2  54  12-24 hours late  S29  2  55  Forgot  S3  2  Forgot  S17  2  Forgot  S18  2  Forgot  S19  2  56  Forgot  S14  2  Forgot  S26  2  57  Forgot  S15  2   Total  58 receiving THR for osteonecrosis were significantly younger (P < 0.001) than those operated on for osteoarthritis (48.3 vs. 61.5 years), and more frequently in the incomplete compliance group (P = 0.037). On the other hand, no significant inter-group differences emerged for gender, age MMS category or long-course treatment. During the study period, one patient showed symptomatic thrombosis at S28, 2 days before termination of S1-S5 S6-S10 S1 1-S15 S16-S20 S21-S25
Study day (aŌer discharge) (Table 5 ). In the 55 echo-Dopplers, four asymptomatic distal thromboses were found at S30 ± 5:
S26-S30
• two suggesting thrombosis in regression or thrombosis sequelae, leading to cessation of preventive anticoagulants; • two distal thromboses, in which anticoagulant therapy was continued; one of these patients had a history of post-surgical venous thrombosis.
These four patients were in the complete compliance group.
There were no revisions for hemorrhagic complications, including the ''over-compliant'' patient who took three capsules at S1 and S2.
Discussion
The present study sought to measure precisely the degree of compliance with oral thromboprophylaxis following THR, and to assess the possible consequences of non-compliance. The study hypothesis was confirmed, with an overall compliance rate of 98.1%. This is a short preventive treatment, in which the patient is not stimulated to comply by symptoms. The impact of therapeutic education in long-course treatment remains to be demonstrated [4] . As in the case of any drug, the patient should receive the most complete information possible at the time of prescription [9] ; this was the case in the present study, where all patients were informed of the study design and objectives. No specific documentary information, however, was given to the patient except for the information letter approved by the ethics committee. This letter may have influenced compliance, in a positive direction, but was integral to good clinical practice. This was the first study of compliance in primary short-course thromboprophylaxis. Previous reports focused on long-course regimes, secondary prevention or curative treatment for known pathologies, with compliance ranging from 31% to 83% [7, 10] . Compliance was found to diminish over time [11, 12] , whatever the pathology [7] ; in long-course treatment, non-compliance impacted efficacy [13, 14] and mortality [15] . The present study likewise found a fall in compliance over time, although remaining greater than 97%.
Dabigatran etexilate was chosen as being the first of the new oral anticoagulants to receive market authorization for this indication in France. The daily 2-capsule dose might tend to increase the risk of poor compliance [7, 16] . The original electronic device recorded administration time without undoing the packaging; the electronic pill-dispenser used in most compliance studies would not have been suitable for a 2-capsule dose, and moreover entails repackaging. Blood assay could have been used to check compliance, but might have biased it and, above all, would have made this observational study interventional. Patients on a low-dose regime were excluded in order to avoid methodological error. The non-inclusion rate in the study was high. All those discharged to an institution where care-staff administer medication were excluded. This was also the reason for restricting the study to THR: in our institution, TKR cases are systematically discharged to a rehabilitation center. The population may thus seem to have been selected, but in practice matched a population undergoing postoperative care at home: younger, with less dependence or comorbidity than the general THR population. This is the population bearing responsibility for their own treatment. In the present study, family members administered the capsules in five cases: two were compliant, and three committed at least one omission.
The risk of symptomatic venous thrombosis following THR ranges in the literature from 1.3% to 2.7% [3, 5, 17, 18] , with a 13% rate of asymptomatic venous thrombosis [3, 17] . A 35-40 days preventive anticoagulant regime has been shown to reduce thrombosis risk from 3.3% to 1.3% [18] . The risk of major hemorrhagic accident is 0.7% to 0.9% [3, 19] , and higher in the first 10 postoperative days [20] , at 0.1-3.1% [21] . The present study was not intended to demonstrate drug efficacy; the observed events rate, however, was comparable to that in the literature. The risk of thrombosis diminishes over time (with distance from surgery and resumption of walking); it is particularly high during the first 15-17 days post-surgery [5, 22] . The two distal thromboses found on echo-Doppler at end of follow-up received no curative treatment, as continuation of the preventive doses was sufficient [23] . During the first 15-17 days, seven patients showed non-compliance. Only one, with omission at postoperative day 10, showed symptomatic DVT; no causal relation can, obviously, be proven. Patient 14 took a higher dose of anticoagulants than prescribed, but without hemorrhage. Other omissions had no detectable clinical impact. The 12 patients with later non-compliance suffered no thromboembolic consequences. With a half-life of 17 hours, the equilibrium state of dabigatran etexilate is extinguished after 3 days' treatment [9, 24] . The consequences of omission are less than with molecules of longer half-life [4] . There is no thrombotic rebound effect with end of treatment [25] . The efficacy of oral anticoagulants is now proven [19, 23, 25, 26] ; over and above the comfort of the patient, who is not subjected to daily injection and weekly blood sampling, they also entail substantial costsaving [6] .
Comparing the complete and incomplete compliance groups found no age difference, although non-retired patients and those operated on for osteonecrosis were significantly younger and less compliant. To maximize compliance, especially in younger patients, the prescriber needs to inform the patient and explain the prescription, particularly in preventive treatment [9, 12] .
The question arises of compliance with long-course oral treatment, notably in cardiological indications [13] . Recent studies of respectively 18,113 [27] and 14,264 patients [28] at 2 years' follow-up at least demonstrated non-inferiority with respect to warfarin. It follows that either compliance was satisfactory or incomplete compliance was compatible with good results in comparison to a treatment in which efficacy is controlled.
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